NCT05307328: An ongoing trial by Sparrow Pharmaceuticals
This trial is ongoing. It must report results 7 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05307328 |
|---|---|
| Title | SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2022 |
| Completion date | Aug. 1, 2025 |
| Required reporting date | Aug. 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |